Plus Therapeutics Inc (PSTV) Stock Price, Quote & News

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat va...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 255 7194

Fax: 210 974 6901

Website: plustherapeutics.com

Address:

6420 LEVIT GREEN BOULEVARD, SUITE 210, Houston, United States

MCapitalJ Jun. 4 at 3:35 PM

$PSTV $SLS OFC these two decide to micro pump now. 🤠😂

0 · Reply

flywithfitz81 Jun. 4 at 2:13 PM

$PSTV 🎵Scammity Scam Scam, Scammity Scam Scam🎵

1 · Reply

zzzzzzzzzzzxxx Jun. 4 at 2:03 PM

$PSTV pump before the dilution

0 · Reply

nobodyyk Jun. 4 at 1:47 PM

$PSTV place trust in me. Mo is no longer the one with the key here. I am. Put your wealth here and your descendants will live in palaces. I am the tree and the tree is me.

1 · Reply

DARKP00L Jun. 4 at 11:51 AM

$PSTV 07:32 on Jun. 04 2026 Plus Therapeutics Subsidiary's Clinical Laboratory Gets Accreditation From College Of American Pathologists #tradeideas

0 · Reply

plustherapeutics Jun. 4 at 11:51 AM

$PSTV announces that its Houston-based clinical laboratory has received accreditation from the College of American Pathologists (CAP) following a recent on-site inspection conducted under the CAP Laboratory Accreditation Program, recognized as the “gold standard” in laboratory accreditation. As part of this distinction, CNSide Diagnostics’ laboratory underwent a rigorous on-site inspection evaluating clinical protocols, documentation, quality control procedures, personnel qualifications, equipment, facilities, safety programs, and overall laboratory management. CNSide now joins more than 8,000 CAP-accredited laboratories worldwide. Full press release here: https://bit.ly/4o5d4Um

1 · Reply

zzzzzzzzzzzxxx Jun. 4 at 11:31 AM

$PSTV friday coming

0 · Reply

supplySHOCK Jun. 4 at 10:15 AM

$LNZA $PSTV $FISK $ARBB yin

0 · Reply

zzzzzzzzzzzxxx Jun. 4 at 3:44 AM

$PSTV real longs need lower.

0 · Reply

zzzzzzzzzzzxxx Jun. 4 at 3:43 AM

$PSTV dilution and fiasco no asco

0 · Reply

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

Jun 2, 2026, 8:00 AM EDT - 2 days ago

Plus Therapeutics Registration statement: Registration filing

2026-06-02T10:13:30.000Z - 2 days ago

Plus Therapeutics files $100M mixed securities shelf

2026-05-26T13:10:52.000Z - 9 days ago

Plus announces presentation of health economics study on CNSide CSF assay

May 26, 2026, 7:30 AM EDT - 9 days ago

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

2026-05-19T11:35:32.000Z - 16 days ago

Plus Therapeutics enters pact with Ephemeral for AI execution platform

May 19, 2026, 7:30 AM EDT - 16 days ago

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

2026-05-15T20:11:34.000Z - 20 days ago

Plus Therapeutics reports Q1 EPS ($1.05), consensus (87c)

May 15, 2026, 4:05 PM EDT - 20 days ago

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

May 15, 2026, 4:00 PM EDT - 20 days ago

Plus Therapeutics Earnings release: Q1 2026

May 15, 2026, 4:00 PM EDT - 20 days ago

Plus Therapeutics Quarterly report: Q1 2026

May 14, 2026, 9:00 AM EDT - 21 days ago

Plus Therapeutics Transcript: AGM 2026

May 8, 2026, 7:30 AM EDT - 27 days ago

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

May 8, 2026, 7:00 AM EDT - 27 days ago

Plus Therapeutics Slides: FY 2026

May 7, 2026, 7:30 AM EDT - 4 weeks ago

Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

Apr 28, 2026, 7:30 AM EDT - 5 weeks ago

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Apr 23, 2026, 7:30 AM EDT - 6 weeks ago

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

Apr 22, 2026, 4:30 PM EDT - 6 weeks ago

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2026-04-21T11:59:57.000Z - 6 weeks ago

Plus Therapeutics regains compliance with Nasdaq minimum bid price requirement

Apr 21, 2026, 7:30 AM EDT - 6 weeks ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 15, 2026, 7:30 AM EDT - 7 weeks ago

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

2026-04-09T11:57:58.000Z - 2 months ago

Plus Therapeutics appoints Eric Daniels as chief development officer

Apr 9, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Appoints Eric J. Daniels, M.D.

2026-04-08T11:39:50.000Z - 2 months ago

Plus Therapeutics granted Orphan Drug Designation for Reyobiq

Apr 8, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

2026-04-07T15:15:27.000Z - 2 months ago

Plus Therapeutics price target lowered to $12 from $37.50 at Maxim

2026-04-07T11:55:34.000Z - 2 months ago

Plus CNSide Cerebrospinal Fluid Tumor Cell Enumeration test gets AMA PLA code

Apr 7, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

2026-04-06T22:20:10.000Z - 2 months ago

Plus Therapeutics’ treatment of malignant glioma granted FDA orphan designation

Apr 2, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

2026-04-01T23:50:16.000Z - 2 months ago

Plus Therapeutics Inc (USA) trading halted, news pending

2026-03-31T14:45:55.000Z - 2 months ago

Plus Therapeutics downgraded to Hold from Buy at D. Boral Capital

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Plus Therapeutics Proxy statement: Proxy filing

Mar 31, 2026, 8:00 AM EDT - 2 months ago

Plus Therapeutics Proxy statement: Proxy filing

2026-03-31T11:38:10.000Z - 2 months ago

Plus Therapeutics announces 1-for-25 reverse stock split

Mar 26, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

2026-03-19T12:01:47.000Z - 2 months ago

Plus Therapeutics’ CNSide assay may reduce healthcare costs

Mar 19, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

2026-03-12T21:05:16.000Z - 3 months ago

Plus Therapeutics reports Q4 EPS (29c), consensus (4c)

Mar 12, 2026, 4:15 PM EDT - 3 months ago

Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Plus Therapeutics Earnings release: Q4 2025

Mar 12, 2026, 7:00 AM EDT - 3 months ago

Plus Therapeutics Annual report: Q4 2025

2026-02-25T12:39:49.000Z - 3 months ago

Plus announces new Category III CPT code for CED used with Reyobiq

Feb 25, 2026, 7:30 AM EST - 3 months ago

Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

2026-02-03T13:40:32.000Z - 4 months ago

Plus Therapeutics initiated with a Buy at Lake Street

2026-01-23T15:00:32.000Z - 4 months ago

Plus Therapeutics price target lowered to $1.50 from $3 at Maxim

2026-01-23T11:11:22.000Z - 4 months ago

Plus Therapeutics price target lowered to $1 from $2 at H.C. Wainwright

Jan 22, 2026, 9:00 AM EST - 4 months ago

Plus Therapeutics Transcript: Business update

Jan 22, 2026, 9:00 AM EST - 4 months ago

Plus Therapeutics Press release: Business update

Jan 22, 2026, 9:00 AM EST - 4 months ago

Plus Therapeutics Slides: Business update

2026-01-22T12:50:20.000Z - 4 months ago

Plus Therapeutics announces anticipated milestones for FY26

Jan 21, 2026, 4:15 PM EST - 4 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

Jan 14, 2026, 8:00 AM EST - 5 months ago

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

Jan 9, 2026, 7:00 AM EST - 5 months ago

Plus Therapeutics Registration statement: Registration Filing

Jan 8, 2026, 7:30 AM EST - 5 months ago

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

Dec 11, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Expands CNSide Assay Platform to State of California

Dec 9, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

Dec 4, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Dec 1, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Nov 24, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Nov 20, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Nov 17, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Nov 6, 2025, 7:30 AM EST - 7 months ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Oct 30, 2025, 5:00 PM EDT - 7 months ago

Plus Therapeutics Quarterly report: Q3 2025

Oct 30, 2025, 5:00 PM EDT - 7 months ago

Plus Therapeutics Earnings release: Q3 2025

Oct 30, 2025, 4:15 PM EDT - 7 months ago

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 21, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Sep 25, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 22, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 18, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 2, 2025, 4:15 PM EDT - 9 months ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 18, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 15, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 14, 2025, 4:15 PM EDT - 10 months ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Aug 14, 2025, 4:00 PM EDT - 10 months ago

Plus Therapeutics Quarterly report: Q2 2025

Aug 14, 2025, 4:00 PM EDT - 10 months ago

Plus Therapeutics Earnings release: Q2 2025

Aug 14, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Aug 12, 2025, 8:00 AM EDT - 10 months ago

Plus Therapeutics Registration statement: Registration Filing

Aug 1, 2025, 8:00 AM EDT - 10 months ago

Plus Therapeutics Proxy statement: Proxy Filing

Jul 31, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Jul 23, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Jul 21, 2025, 8:00 AM EDT - 11 months ago

Plus Therapeutics Proxy statement: Proxy Filing

Jul 15, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Jul 11, 2025, 8:00 AM EDT - 11 months ago

Plus Therapeutics Proxy statement: Proxy Filing

Jul 10, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Jul 8, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 30, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 26, 2025, 9:00 AM EDT - 1 year ago

Plus Therapeutics Transcript: Business Update

Jun 26, 2025, 9:00 AM EDT - 1 year ago

Plus Therapeutics Press release: Business Update

Jun 26, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Jun 25, 2025, 4:15 PM EDT - 1 year ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Jun 25, 2025, 7:30 AM EDT - 1 year ago

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

MCapitalJ Jun. 4 at 3:35 PM

$PSTV $SLS OFC these two decide to micro pump now. 🤠😂

0 · Reply

flywithfitz81 Jun. 4 at 2:13 PM

$PSTV 🎵Scammity Scam Scam, Scammity Scam Scam🎵

1 · Reply

zzzzzzzzzzzxxx Jun. 4 at 2:03 PM

$PSTV pump before the dilution

0 · Reply

nobodyyk Jun. 4 at 1:47 PM

$PSTV place trust in me. Mo is no longer the one with the key here. I am. Put your wealth here and your descendants will live in palaces. I am the tree and the tree is me.

1 · Reply

DARKP00L Jun. 4 at 11:51 AM

$PSTV 07:32 on Jun. 04 2026 Plus Therapeutics Subsidiary's Clinical Laboratory Gets Accreditation From College Of American Pathologists #tradeideas

0 · Reply

plustherapeutics Jun. 4 at 11:51 AM

1 · Reply

zzzzzzzzzzzxxx Jun. 4 at 11:31 AM

$PSTV friday coming

0 · Reply

supplySHOCK Jun. 4 at 10:15 AM

$LNZA $PSTV $FISK $ARBB yin

0 · Reply

zzzzzzzzzzzxxx Jun. 4 at 3:44 AM

$PSTV real longs need lower.

0 · Reply

zzzzzzzzzzzxxx Jun. 4 at 3:43 AM

$PSTV dilution and fiasco no asco

0 · Reply

supplySHOCK Jun. 3 at 9:40 PM

$FGI $FABC $LNZA $PSTV list

0 · Reply

supplySHOCK Jun. 3 at 7:46 PM

$BCAB $AIIO $PSTV info

0 · Reply

andre82 Jun. 3 at 5:06 PM

$PSTV fake account but ill indulge out of boredom. Your only 5 years late, good luck!

1 · Reply

qnfrhc Jun. 3 at 4:53 PM

$PSTV "I have just sent a formal protest letter to Plus Therapeutics management regarding their predatory dilution tactics. I'm done being silent. I encourage others to do the same."

0 · Reply

Investor1862 Jun. 3 at 4:25 PM

$PSTV slow creep back below 1 dollar...catch a load more retail investors with a pipe dream...another reverse split... repeat process.

1 · Reply

andre82 Jun. 3 at 4:07 PM

$PSTV i bet sub 4 dollars before dilution and around 2.5 after. My target price remains 0.1 presplit, that is 2.5 now.

0 · Reply

zzzzzzzzzzzxxx Jun. 3 at 3:14 PM

$PSTV

0 · Reply

Trident1014 Jun. 3 at 2:31 PM

$PSTV I'll take my profit and revisit later

0 · Reply

plustherapeutics Jun. 3 at 2:14 PM

#CNSideDiagnostics is exhibiting at Best of #ASCO 2026 in Austin, Texas later this month. This event is a a free CME opportunity designed for oncology clinicians, researchers, and allied health professionals seeking the latest updates in cancer care. If you are attending, we invite you to stop by the #CNSide booth to connect with our team and learn how our diagnostic platform supports precision neuro-oncology. Read more about the event and register: bit.ly/3QjzxAD $PSTV

1 · Reply

andre82 Jun. 3 at 1:36 PM

$PSTV Stay patient. Mo is bending over to the shorts a while longer. 🤣

0 · Reply

Marketmoverjoe Jun. 2 at 9:56 PM

$PSTV Will this be a slow bleed. Anyone have perspective on this or does anyone care?

1 · Reply

Marketmoverjoe Jun. 2 at 8:59 PM

$PSTV love the timing of this mixed shelf BS too.

0 · Reply

Market Cap	40.06M
Revenue (ttm)	5.21M
Net Income (ttm)	-22.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-429.75%
Debt to Equity Ratio	0.06

Volume	102,900
Avg Vol	351,835
Day's Range	N/A - N/A
Shares Out	6.88M
Stochastic %K	31%
Beta	1.40
Analysts	Sell
Price Target	$38.50